Scoping review synthesizes immunosuppressive strategies and outcomes in solid organ transplantation
New Drug Strategies Aim to Stop Your Body From Rejecting a Transplant
This scoping review examines immunosuppressive strategies for solid organ transplant patients, including conventional, biologic, and emergin…
New drug strategies aim to stop your body from attacking a new organ, protecting transplants longer while reducing dangerous side effects fr…
Phase 2a trial of dazodalibep plus belatacept shows 25% acute rejection rate in kidney transplant patients
Early study tests two-drug combination to prevent kidney transplant rejection
A phase 2a, open-label, single-arm trial in 23 adults undergoing first kidney transplants evaluated dazodalibep plus belatacept as sole main…
A new two-drug kidney treatment was safe but failed to prevent rejection in most patients during this early study.